These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1471423)

  • 21. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
    Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
    Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stimulation of chemiluminescence and resistance against aerogenic influenza virus infection by synthetic muramyl dipeptide combined with trehalose dimycolate.
    Masihi KN; Brehmer W; Azuma I; Lange W; Müller S
    Infect Immun; 1984 Jan; 43(1):233-7. PubMed ID: 6317568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenic properties of soluble antigens or whole cells of Brucella abortus strain 45/20 associated with immunoadjuvants. I. Soluble antigens.
    Woodard LF; Toone NM; McLaughlin CA
    Can J Comp Med; 1980 Oct; 44(4):453-5. PubMed ID: 6778599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunomodifiers of bacterial origin.
    Le Garrec Y
    Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):137-41. PubMed ID: 3791953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonpyrogenic Molecular Adjuvants Based on norAbu-Muramyldipeptide and norAbu-Glucosaminyl Muramyldipeptide: Synthesis, Molecular Mechanisms of Action, and Biological Activities in Vitro and in Vivo.
    Effenberg R; Turánek Knötigová P; Zyka D; Čelechovská H; Mašek J; Bartheldyová E; Hubatka F; Koudelka Š; Lukáč R; Kovalová A; Šaman D; Křupka M; Barkocziova L; Kosztyu P; Šebela M; Drož L; Hučko M; Kanásová M; Miller AD; Raška M; Ledvina M; Turánek J
    J Med Chem; 2017 Sep; 60(18):7745-7763. PubMed ID: 28829599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
    Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
    Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of muramyl dipeptide and trehalose dimycolate on resistance of mice to Toxoplasma gondii and Acanthamoeba culbertsoni infections.
    Masihi KN; Bhaduri CR; Werner H; Janitschke K; Lange W
    Int Arch Allergy Appl Immunol; 1986; 81(2):112-7. PubMed ID: 3759255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection of ruminants by Pasteurella haemolytica A1 capsular polysaccharide vaccines containing muramyl dipeptide analogs.
    Brogden KA; DeBey B; Audibert F; Lehmkuhl H; Chedid L
    Vaccine; 1995 Dec; 13(17):1677-84. PubMed ID: 8719519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Muramyl dipeptide derivative and its clinical application].
    Tsubura E
    Kekkaku; 1989 Nov; 64(11):731-9. PubMed ID: 2593464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of immune responses by muroctasin.
    Akasaki M
    Arzneimittelforschung; 1988 Jul; 38(7A):976-7. PubMed ID: 3056427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Biochemical and immunological properties of the fractions of tubercle bacilli].
    Azuma I
    Kekkaku; 1998 Feb; 73(2):65-70. PubMed ID: 9545698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
    Ishihara C; Yamamoto K; Hamada N; Azuma I
    Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
    Yoo YC; Saiki I; Sato K; Azuma I
    Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New developments in the field of synthetic muramyl peptides, especially as adjuvants for synthetic vaccines.
    Lederer E
    Drugs Exp Clin Res; 1986; 12(6-7):429-40. PubMed ID: 3527628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomes, muramyl dipeptide derivatives, and nontoxic lipid A derivatives as adjuvants for human malaria vaccines.
    Hui GS
    Am J Trop Med Hyg; 1994; 50(4 Suppl):41-51. PubMed ID: 8172331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigenicity study of muroctasin.
    Yamaguchi F; Hattori H; Wagai N; Tsukada W
    Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A synthetic adjuvant effective in inducing antitumor immunity.
    Kataoka T; Tokunaga T
    Jpn J Cancer Res; 1988 Jul; 79(7):817-20. PubMed ID: 3139596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient genetically controlled formation of antibody to a synthetic antigen [poly(LTyr, LGlu)-poly(DLAla)- -poly(LLys)] covalently bound to a synthetic adjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine).
    Mozes E; Sela M; Chedid L
    Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4933-7. PubMed ID: 6776530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Muroctasin. A new muramyl dipeptide derivative, MDP-Lys(L18).
    Arzneimittelforschung; 1988 Jul; 38(7A):951-1074. PubMed ID: 3190801
    [No Abstract]   [Full Text] [Related]  

  • 40. [New technology of vaccine production--international prospect of the development. Development of synthetic immunologic adjuvants and MDP-antigen binding vaccines].
    Azuma I
    Nihon Rinsho; 1987 Oct; 45(10):2355-61. PubMed ID: 3448269
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.